Weight-based combination therapy with peginterferon alpha-2b and ribavirin for Naïve, relapser and non-responder patients with chronic hepatitis C

Página do item simplificado
dc.contributor.authorGonçales Junior, Fernando Lopes
dc.contributor.authorVigani, Aline
dc.contributor.authorGonçales, Neiva
dc.contributor.authorBarone, Antonio Alci
dc.contributor.authorAraújo, Evaldo
dc.contributor.authorFocaccia, Roberto
dc.contributor.authorOliveira, Umbeliana
dc.contributor.authorCoelho, Henrique Sérgio Morais
dc.contributor.authorPaixao, Jacqueline
dc.contributor.authorPerez, Renata de Mello [UNIFESP]
dc.contributor.authorLobato, Cirley
dc.contributor.authorWeirich, Judith
dc.contributor.authorRosa, Heitor
dc.contributor.authorBorges, Andrelina
dc.contributor.authorVila, Ricardo
dc.contributor.authorCorrêa-Giannella, Maria Lúcia
dc.contributor.authorFerraz, Maria Lucia Cardoso Gomes [UNIFESP]
dc.contributor.institutionFaculty of Medical Sciences of Campinas
dc.contributor.institutionSão Paulo University School of Medicine
dc.contributor.institutionEmilio Ribas Institute
dc.contributor.institutionFederal University of Rio de Janeiro
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionSecretary of Health of Acre
dc.contributor.institutionFederal University of Goiás
dc.contributor.institutionSchering-Plough Brazil
dc.contributor.institutionSão Paulo University Medical School Laboratory of Medical Investigations
dc.date.accessioned2015-06-14T13:36:28Z
dc.date.available2015-06-14T13:36:28Z
dc.date.issued2006-10-01
dc.description.abstractCombination therapy with pegylated interferon and ribavirin is considered the new standard therapy for naïve patients with chronic hepatitis C. We evaluated the efficacy and safety of treatment with weight-based peginterferon alpha-2b (1.5 mg/kg per week) plus ribavirin (800-1,200 mg/day) for 48 weeks in naïve, relapser and non-responder (to previous treatment with interferon plus ribavirin) patients with chronic hepatitis C. Sixty-seven naïve, 26 relapser and 40 non-responder patients were enrolled. The overall sustained virological response (SVR) for the intention-to-treat population was 54% for naïve, 62% for relapser and 38% for non-responder patients. In the naïve subgroup, SVR was significantly higher in patients with the non-1 genotype (67%) compared to those with genotype 1 (45%). In relapsers and non-responders, SVR was, respectively, 69% and 24% in patients with genotype 1 and 43% and 73% in those with genotype non-1. There were no significant differences in SVR rates among the three body weight ranges (< 65 kg, 65-85 kg and > 85 kg) in any of the subgroups. Early virological response (EVR) was reached by 78%, 81% and 58% of naïve, relapser and non-responder patients, respectively, and among those with EVR, 63%, 67% and 61%, respectively, subsequently achieved SVR. All of the non-responder patients who did not have EVR reached SVR. Treatment was discontinued in 13% of the patients, due to loss to follow-up, hematological abnormalities or depression.en
dc.description.affiliationFaculty of Medical Sciences of Campinas
dc.description.affiliationSão Paulo University School of Medicine
dc.description.affiliationEmilio Ribas Institute
dc.description.affiliationFederal University of Rio de Janeiro
dc.description.affiliationFederal University of São Paulo
dc.description.affiliationSecretary of Health of Acre
dc.description.affiliationFederal University of Goiás
dc.description.affiliationSchering-Plough Brazil
dc.description.affiliationSão Paulo University Medical School Laboratory of Medical Investigations
dc.description.affiliationUnifespUNIFESP, EPM
dc.description.sourceSciELO
dc.format.extent311-316
dc.identifierhttp://dx.doi.org/10.1590/S1413-86702006000500002
dc.identifier.citationBrazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 10, n. 5, p. 311-316, 2006.
dc.identifier.doi10.1590/S1413-86702006000500002
dc.identifier.fileS1413-86702006000500002.pdf
dc.identifier.issn1413-8670
dc.identifier.scieloS1413-86702006000500002
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/3292
dc.language.isoeng
dc.publisherBrazilian Society of Infectious Diseases
dc.relation.ispartofBrazilian Journal of Infectious Diseases
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectHepatitis Cen
dc.subjectinterferon alpha-2ben
dc.subjecttherapyen
dc.titleWeight-based combination therapy with peginterferon alpha-2b and ribavirin for Naïve, relapser and non-responder patients with chronic hepatitis Cen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
S1413-86702006000500002.pdf
Tamanho:
63.34 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos